BioVenture VoiCes Episode 33: Pappas Capital's Art Pappas
Art Pappas describes his early career, which involved numerous overseas posts for large companies, and how it let him to eventually found Pappas Capital. He discusses the various ways the firm invests, and how having corporates partners as LPs and co-investors has been a recipe for success. Chapters Intro and early life - 0:54 International work – 7:12 Takeaways from working for companies – 10:44 Understanding drug development – 16:22 Pappas Capital – 18:47 Helping universiti
2 hours ago
Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks
She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics. Chapters General take on biotech - 0:52 Arrivent BioPharma - 4:20 Oruka Therapeutics - 6:46 Jade Biosciences - 9:18 Zura Bio - 12:07 Other catalysts / Pavella - 16:02
4 days ago
Benchling’s Sandy Li breaks down new survey data showing biotech’s first AI “killer apps” (literature review, knowledge extraction) are already mainstream
The biggest limiter, until now, has been data quality and integration across R&D systems. That is changing and the potential use cases are expanding rapidly.
5 days ago
.png){kind=logo}
